Earnings Call Summary | CRA International(CRAI.US) Q2 2024 Earnings Conference
Earnings Call Summary | CRA International(CRAI.US) Q2 2024 Earnings Conference
The following is a summary of the CRA International, Inc. (CRAI) Q2 2024 Earnings Call Transcript:
以下是CRA國際2024年第二季度業績會簡報:
Financial Performance:
金融業績:
CRA International reported a 5.9% increase in Q2 2024 revenue to $171.4 million.
Non-GAAP net income, earnings per diluted share, and EBITDA increased by 26.4%, 28.9%, and 18.5% respectively.
For FY 2024, CRA expects revenue in the range of $670 million to $685 million and a non-GAAP EBITDA margin between 12.2% to 13.0%.
CRA國際報告2024年第二季度營業收入增長5.9%,至171.4百萬美元。
非通用會計淨利潤、攤薄每股收益和息稅折舊及攤銷前利潤分別增長了26.4%、28.9%和18.5%。
截至2024財年,CRA預計營業收入區間在6,700到6,850百萬美元之間,非GAAP息稅折舊及攤銷前利潤率在12.2%到13.0%之間。
Business Progress:
業務進展:
Significant contributions from the Antitrust & Competition Economics, Financial Economics, Intellectual Property, Labor & Employment, and Life Sciences practices, with growth in new project originations.
The company optimized its service portfolio by reconfiguring the consulting team, which involved targeted actions in about half a dozen practices.
Intellectual Property practice has expanded, particularly in Texas, enhancing CRA's capabilities in patent litigation.
反壟斷與競爭經濟學、金融經濟學、知識產權、勞動與就業和生命科學等領域做出了重要貢獻,新項目的起源有所增長。
公司通過重新配置諮詢團隊優化了其服務組合,這涉及到大約六個實踐領域的有針對性的行動。
知識產權實踐在得克薩斯州特別是在專利訴訟方面擴展,增強了在專利訴訟方面的能力。
Opportunities:
機會:
The Antitrust & Competition Economics practice continues to see strong demand in regulatory and legal environments, handling high-profile litigation and assisting in mergers.
Intellectual Property practice benefits from a strong demand for patent litigation, especially from their strengthened position in Texas.
反壟斷與競爭經濟學實踐在監管和法律環境中繼續看到強勁的需求,處理高調訴訟並協助合併。
知識產權實踐從對在得克薩斯州的地位的加強中受益,尤其是在專利訴訟方面有強烈的需求。
Risks:
風險:
There are pockets of excess capacity within the company, leading to targeted optimization actions.
公司內部有一些超額產能,導致了有針對性的優化行動。
More details: CRA International IR
更多細節請訪問:CRA國際IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。